2026-10907RuleWallet

FDA Clears Real-Time Ultrasound Labeling Device

Published Date: 6/1/2026

Rule

Summary

The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.

Analyzed Economic Effects

4 provisions identified: 2 benefits, 2 costs, 0 mixed.

Device moved to Class II

The FDA has classified the real-time ultrasound anatomy visualization and labeling device for ultrasound guided regional anesthesia as Class II (special controls). This final order is effective June 1, 2026 and the classification was applicable on October 18, 2022; FDA says the change reduces regulatory burdens and will enhance patients' access to this technology, potentially saving time and money for device makers and hospitals.

510(k) Premarket Notification Required

FDA states that real-time ultrasound anatomy visualization and labeling devices are subject to premarket notification under section 510(k). At this time FDA has not exempted this device type under section 510(m), so manufacturers must use the 510(k) process to market the device.

Required Special Controls and Tests

To be in Class II, manufacturers must meet special controls including: clinical performance testing of location accuracy, human factors testing showing users can identify structures from the instructions, software verification/validation and hazard analysis (including compatibility with labeled ultrasound devices), and labeling that includes recommended training, clinical data details, and a warning against over-reliance.

Serves as Predicate for Future Devices

FDA states the De Novo classification allows this device type to serve as a predicate for future devices, so other sponsors can rely on the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Rule Effective
6/1/2026
6/1/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register